- ￥200
- gemig
- XF-J0722
- 2025年07月15日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 规格：
50mg
产品货号：XF-J0722
产品规格：50mg
产品包装：瓶
储存条件及有效期：详见标签
本产品仅供科研实验用，不做其他用途！
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Genotyping Anti-Hepatitis B Virus Drug Resistance
, such as lamivudine and adefovir (1 ). Currently, the only therapies approved in the United States for treatment of chronic HBV infection are IFN-α and lamivudine. However, a number of nucleoside and nucleotide analogs are in development, and it is likely
(4 ). While the survival rate for HCC is 5 ). Interferon produces a sustained virus response in only about 20% of patients following the end of therapy (5 ,6 ). Lamivudine is highly effective against both virus and liver disease, although a high rate of virus resistance
Designing Clinical Development Programs for Anti-Hepatitis B Virus Drugs
hepatitis B—interferon, lamivudine, and adefovir—allow clinical management of some patients but are associated with frequent nonresponse (interferon), frequent viral resistance (lamivudine), or potential safety issues (adefovir), so additional treatment
技术资料暂无技术资料 索取技术资料
